Key Metrics of Eli Lilly and Company
Revenue$34.1B▲ 19.6% YoYFY 2023
Operating income—
Net profit$5.2B▼ 16.1% YoY
Shareholders' equity$10.8B
Market cap$1.2TLLY · $1,306.69
Competitors10identified
About Eli Lilly and Company
Sectors
Company details
- Website
- lilly.com
- Registered office
- Atrium Place, 11th Floor, Tower-2, Block C, Vanijya Nikunj, Udyog Vihar, Phase V, Sector 19, Industrial Complex Dundahera, Industrial Complex Dundahera, Gurgaon, In-hr, 122016
- Listed
- NYSE: LLY
Operational Areas of Eli Lilly and Company
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Entity details
CINU24239HR1993PTC034844
LEI code335800W8CVQFHHA3GI20
State codeHR
PIN code122016
Current legal nameELI LILLY AND COMPANY
Classification—
Listing statusUnlisted
Registration no.034844
Company age—
PAN—
CountryUnited States
CityGurgaon
StateHaryana
Current statusActive
Date of incorporation—
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—
Compliance
Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026
Industry classification
NIC code24239
Description of main activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
Description of business activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
US market & SEC filings
LLY · NYSE · SEC CIK 0000059478
Last price · 23 Oct 2026
$1,306.69
+2.83%
Market cap$1.2T
P/E225.3On FY 2023 diluted EPS
Volume2,660,518
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
LLY share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
AGM for FY 2025-2630 Sep 2026
Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026
Statutory due date · 7 days left
MGT-7 for FY 2025-2629 Nov 2026
Statutory due date · 37 days left
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeATRIUM PLACE, 11TH FLOOR, TOWER-2, BLOCK C, VANIJYA NIKUNJ, UDYOG VIHAR, PHASE V, SECTOR 19, INDUSTRIAL COMPLEX DUNDAHERA, INDUSTRIAL COMPLEX DUNDAHERA, GURGAON, IN-HR, 122016
GSTIN—
Email—
Websitehttps://www.lilly.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Eli Lilly and Company
Competitors10identified
Locations1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | hcahealthcare.com | 2011 | United States |
Similar companies
B
Brooks Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
M
Morepen Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
N
Nectar Lifesciences LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
T
Themis Medicare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Sakar Healthcare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
I
IOL Chemicals and Pharmaceuticals Ltd. (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
P
Poly Medicure (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Suven Life Sciences (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Group companies
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.